⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Cardiac Lymphatic Rarefaction and Aging
Current understanding
Age-related loss (rarefaction) of cardiac lymphatic vessels is proposed as an upstream driver of cardiac inflammaging, plausibly by impairing clearance of interstitial fluid, immune cells, and inflammatory mediators from the aging myocardium [mechanism-plausible]. Current support is title-level from a preclinical report [animal-model]; direct human evidence and quantitative lymphatic-density–inflammation coupling data are not yet on the page. Sits within a broader but sparsely populated ‘lymphatic aging’ axis distinct from blood-vessel vascular aging.
Evidence log
- 2026-09-15 — Lymphatic rarefaction drives cardiac inflammaging.: cross-connection with inflammaging: Positions lymphatic vessel loss as a clearance-failure mechanism upstream of cardiac inflammaging, distinct from SASP-, mtDNA-, or complement-driven origins already catalogued. (novelty: 3)
Open questions
Related
Contributing findings
Lymphatic rarefaction drives cardiac inflammaging.
15-sep-2026
novelty 3
per-area 3
introduces